Regarding the lack of transparency in technical documents for the treatment of patients with COVID-19 in Peru

• Autor(a) principal: Taype-Rondan, Alvaro
• Data de Publicação: 2020
• Outros Autores: Herrera-Añazco , Percy, Málaga, Germán
• Tipo de documento: preprint
• Idioma: spa
• Título da fonte: SciELO Preprints
• Texto Completo: https://preprints.scielo.org/index.php/scielo/preprint/view/375
• topic: Medicina Basada en la Evidencia; Toma de Decisiones Clínicas; COVID-19; Evidence-Based Medicine; Clinical Decision-Making; COVID-19

The Peruvian Ministry of Health (MINSA, in Spanish) has published ministerial resolutions (RM) with the aim of regulating the treatment of people affected by COVID-19. The last RM published on April 29 includes the use of tocilizumab, corticosteroids, and enoxaparin. These guidelines do not make clear what process was followed to make decisions, how each of these decisions was justified, nor who their authors are or their potential conflicts of interest. It is important to make an effort to promptly make these data transparent, especially in a subject in which there is not yet much evidence, such as COVID-19. In this article, we present controversies on the tocilizumab, corticosteroids, and enoxaparin established by the MINSA, as well as recommendations on the decision-making process.